MEI Pharma's 15min chart shows KDJ Death Cross and Bearish Marubozu.

According to MEI Pharma's 15-minute chart, a KDJ Death Cross and a Bearish Marubozu pattern emerged on August 11, 2025 at 12:30. This indicates that the momentum of the stock price is shifting towards a downward trend and has the potential to continue decreasing. The sellers currently dominate the market, and it is likely that this bearish momentum will persist.

MEI Pharma, a U.S.-listed company, has made a groundbreaking move by investing $100 million in Litecoin (LTC), marking the first time a U.S.-listed firm has adopted Litecoin as a primary treasury asset [1]. This significant investment, announced on August 4, 2025, is led by Charlie Lee, Litecoin’s creator, and has sparked a series of market reactions and analyses.

Key Points of the Investment

MEI Pharma’s investment in Litecoin signals a shift in corporate treasury strategies. The company has allocated $100 million to Litecoin, which was trading at $107.58 before the investment. Post-investment, the price of Litecoin appreciated to $124, enhancing MEI’s asset value to an estimated $110–$115 million [1].

Market Impact and Institutional Adoption

The substantial investment in Litecoin is expected to increase market stability and liquidity. Analysts note that the price appreciation from $107.58 to $124 per LTC reflects the enhanced market confidence and liquidity brought about by MEI Pharma’s investment [1]. This move has not only increased Litecoin’s market cap but has also positioned it as a viable alternative to Bitcoin and Ethereum for corporate treasuries.

ETF Speculation and Market Momentum

Litecoin’s recent surge to a five-month high is primarily driven by MEI Pharma’s $100 million treasury investment, alongside optimistic ETF approval rumors [2]. Litecoin reached $128.40 amid ETF speculation and corporate treasury interest, reflecting a significant boost in market confidence. The ETF approval odds stand at 80% for 2025, according to decentralized prediction platforms, adding optimism to Litecoin’s market performance [2].

Merchant Adoption and Payment Share

Litecoin holds 14.5% of crypto payments on CoinGate, ranking second behind Bitcoin’s 22.9% [2]. This growing merchant adoption reinforces Litecoin’s utility and supports its price momentum, positioning LTC as a leading payment cryptocurrency.

Future Outlook

MEI Pharma’s investment is a landmark move for corporate treasury strategies, reflecting a broader trend of companies converting into crypto investment vehicles [2]. This growing practice could lead to increased institutional demand for Litecoin, potentially stabilizing and elevating LTC’s market position over time.

Conclusion

MEI Pharma’s $100 million investment in Litecoin represents a pivotal moment in the integration of cryptocurrencies into corporate treasury strategies. As institutional interest grows, the landscape of corporate finance may evolve significantly, paving the way for further adoption of digital assets. Investors should watch these developments closely for future opportunities.

References

[1] https://en.coinotag.com/mei-pharmas-100m-move-to-litecoin-exploring-potential-impacts-on-market-dynamics-and-institutional-adoption/
[2] https://en.coinotag.com/litecoin-gains-momentum-amid-etf-speculation-and-mei-pharmas-corporate-treasury-investment/